News | January 27, 2009

Boston Scientific, Medtronic Reach Agreement on Cardiology, Endovascular Repair Patent Disputes

January 28, 2009 - Boston Scientific Corp. and Medtronic Inc. today announced the settlement of two lawsuits and an agreement to stand down in three others.

These agreements stop all current litigation between the two parties in the fields of interventional cardiology and endovascular repair. All the disputes involved intellectual property.

“We are pleased to have reached these agreements which will allow us to focus our efforts and resources on developing new products and therapies that improve patients’ lives,” said Hank Kucheman, senior vice president and group president, cardiovascular for Boston Scientific.

The stand-down agreements are time limited and involve only Medtronic and Boston Scientific. While the terms of the settlement remain confidential, Boston Scientific said the agreements will not have a material impact on its financial results. The lawsuits are listed below.

For more information: www.bostonscientific.com

Related Content

The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.

Technology | Stents | April 03, 2019

New Indication Added for Covered Stent to Treat Hemodialysis AV Fistula

April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market.

Feature | Stents | February 22, 2019 | Dave Fornell, Editor

FDA Clears Biotronik Orsiro Stent That Outperforms Xience

February 22, 2019 — The U.S.

The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor

New Directions and Trends in Coronary Metallic Stents

There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019

Coronary Stent Market Characterized by New Drug-eluting Stents

The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018

Orsiro Stent Performs in Two Comparison Studies Presented at TCT 2018

October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials

Technology | Stents | September 27, 2018

FDA Approves Biotronik's PK Papyrus Stent for Coronary Perforations

September 27, 2018 — Biotronik recently announced U.S.

Videos | Stents | September 11, 2018

VIDEO: How to Implant a Dedicated Bifurcation Stent Using the ABS Stent

This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d

Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

News | Stents | January 25, 2018

Elixir Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017

Titan Nitride Oxide Coated Stent is Noninferior to Synergy Stent

November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente

News | Stents | November 10, 2017

Cordis Showcases Comprehensive Interventional Cardiology Portfolio with Coronary Stents at TCT 2017

Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...